In the latest session, Moderna Inc (NASDAQ: MRNA) closed at $105.11 up 0.82% from its previous closing price of $104.26. In other words, the price has increased by $+0.85 from its previous closing price. On the day, 3042149 shares were traded.
Ratios:
For a deeper understanding of Moderna Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 15 ’24 when Hoge Stephen sold 15,000 shares for $103.17 per share. The transaction valued at 1,547,550 led to the insider holds 1,501,241 shares of the business.
AFEYAN NOUBAR sold 15,000 shares of MRNA for $1,628,031 on Mar 13 ’24. The Director now owns 2,131,931 shares after completing the transaction at $108.54 per share. On Mar 08 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 544 shares for $99.05 each. As a result, the insider received 53,884 and left with 9,267 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 39.83B and an Enterprise Value of 32.47B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.86 while its Price-to-Book (P/B) ratio in mrq is 2.90. Its current Enterprise Value per Revenue stands at 4.81 whereas that against EBITDA is -9.89.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $163.24, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is 99.21, while the 200-Day Moving Average is calculated to be 101.08.
Shares Statistics:
For the past three months, MRNA has traded an average of 4.64M shares per day and 4.72M over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 335.44M. Insiders hold about 12.20% of the company’s shares, while institutions hold 66.01% stake in the company. Shares short for MRNA as of Feb 29, 2024 were 22.11M with a Short Ratio of 4.76, compared to 20.88M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.79% and a Short% of Float of 7.69%.
Earnings Estimates
There are 14 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$3.26 for the current quarter, with a high estimate of -$1.94 and a low estimate of -$4.11, while EPS last year was $0.19. The consensus estimate for the next quarter is -$3.34, with high estimates of -$2.04 and low estimates of -$3.94.
Analysts are recommending an EPS of between -$5.83 and -$8.29 for the fiscal current year, implying an average EPS of -$7.17. EPS for the following year is -$5.2, with 21 analysts recommending between -$1.05 and -$7.6.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $4.73B, while the lowest revenue estimate was $3.69B, resulting in an average revenue estimate of $4.21B. In the same quarter a year ago, actual revenue was $6.85B, down -38.50% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $4.68B in the next fiscal year. The high estimate is $5.88B and the low estimate is $3.23B. The average revenue growth estimate for next year is up 11.10% from the average revenue estimate for this year.
